Cogstate Ltd

CGS.ASX

Health Care

Cogstate Ltd (ASX:CGS) is the neuroscience company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare.

Market Data

Price

$2.550

-0.0%
Market Cap

$444.6M

P/E Ratio

30.2x

EPS

$0.086

Div. Yield

0.77%

52-Week Change

+0.2%

Latest Earnings

Cogstate 1H26 Financial Results

19 February 2026

Revenue
$26.90
+12.0% YoY
NPAT
$4.50
+16.0% YoY

Cogstate delivered strong 1H26 results with revenue up 12% to $26.9M and net profit up 16% to $4.5M, driven by record clinical trial contract wins of $41.7M (up 105%). The company demonstrated operational leverage and diversification success with 45% of new contracts from mood, sleep and neurological conditions beyond Alzheimer's disease. Key points: Record clinical trial sales contracts of $41.7M, up 105% on pcp; Strong diversification with 45% of contracts from mood/sleep/neurological conditions (6x increase); Contracted future revenue increased to $104.9M with record $21.7M expected in 2H26

Recent Announcements

19 Feb 2026 Actual Results Positive

Cogstate 1H26 Financial Results

Cogstate delivered strong 1H26 results with revenue up 12% to $26.9M and net profit up 16% to $4.5M, driven by record clinical trial contract wins of $41.7M (up 105%). The company demonstrated operational leverage and diversification success with 45% of new contracts from mood, sleep and neurological conditions beyond Alzheimer's disease. Key points: Record clinical trial sales contracts of $41.7M, up 105% on pcp; Strong diversification with 45% of contracts from mood/sleep/neurological conditions (6x increase); Contracted future revenue increased to $104.9M with record $21.7M expected in 2H26

Get real-time alerts for CGS

Receive AI-powered earnings summaries and instant notifications when Cogstate Ltd releases results.

Register Free